EA037202B1 - Слитые белки для лечения инфекций, вызванных грамотрицательными бактериями - Google Patents

Слитые белки для лечения инфекций, вызванных грамотрицательными бактериями Download PDF

Info

Publication number
EA037202B1
EA037202B1 EA201270079A EA201270079A EA037202B1 EA 037202 B1 EA037202 B1 EA 037202B1 EA 201270079 A EA201270079 A EA 201270079A EA 201270079 A EA201270079 A EA 201270079A EA 037202 B1 EA037202 B1 EA 037202B1
Authority
EA
Eurasian Patent Office
Prior art keywords
gly
ala
leu
lys
fusion protein
Prior art date
Application number
EA201270079A
Other languages
English (en)
Russian (ru)
Other versions
EA201270079A1 (ru
Inventor
Роб Лавинь
Стефан Миллер
Ивс Брирс
Гёйдо Волкарт
Маартен Валмах
Original Assignee
Катхолике Университейт Лёвен, К.У. Лёвен Р Энд Д
Лисандо Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Катхолике Университейт Лёвен, К.У. Лёвен Р Энд Д, Лисандо Аг filed Critical Катхолике Университейт Лёвен, К.У. Лёвен Р Энд Д
Publication of EA201270079A1 publication Critical patent/EA201270079A1/ru
Publication of EA037202B1 publication Critical patent/EA037202B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723Cationic antimicrobial peptides, e.g. defensins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462Lysozyme (3.2.1.17)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017Lysozyme (3.2.1.17)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
EA201270079A 2009-06-26 2010-06-28 Слитые белки для лечения инфекций, вызванных грамотрицательными бактериями EA037202B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09163953 2009-06-26
PCT/EP2010/059146 WO2010149792A2 (en) 2009-06-26 2010-06-28 Antimicrobial agents

Publications (2)

Publication Number Publication Date
EA201270079A1 EA201270079A1 (ru) 2012-06-29
EA037202B1 true EA037202B1 (ru) 2021-02-18

Family

ID=42799668

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270079A EA037202B1 (ru) 2009-06-26 2010-06-28 Слитые белки для лечения инфекций, вызванных грамотрицательными бактериями

Country Status (17)

Country Link
US (3) US8906365B2 (cg-RX-API-DMAC7.html)
EP (3) EP3714895A3 (cg-RX-API-DMAC7.html)
JP (2) JP6034187B2 (cg-RX-API-DMAC7.html)
KR (2) KR20170024129A (cg-RX-API-DMAC7.html)
CN (2) CN102458452B (cg-RX-API-DMAC7.html)
AU (3) AU2010264656B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1015192A2 (cg-RX-API-DMAC7.html)
CA (1) CA2764131C (cg-RX-API-DMAC7.html)
DK (1) DK2445515T3 (cg-RX-API-DMAC7.html)
EA (1) EA037202B1 (cg-RX-API-DMAC7.html)
ES (1) ES2579806T3 (cg-RX-API-DMAC7.html)
IL (2) IL217124A (cg-RX-API-DMAC7.html)
MX (2) MX360300B (cg-RX-API-DMAC7.html)
PL (1) PL2445515T3 (cg-RX-API-DMAC7.html)
SG (1) SG177370A1 (cg-RX-API-DMAC7.html)
SI (1) SI2445515T1 (cg-RX-API-DMAC7.html)
WO (1) WO2010149792A2 (cg-RX-API-DMAC7.html)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0815484D0 (en) 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
EP3714895A3 (en) 2009-06-26 2020-11-25 Lysando AG Antimicrobial agents
WO2010149795A1 (en) 2009-06-26 2010-12-29 Lysando Holding Establishment Antimicrobial agents
EA024253B1 (ru) 2009-08-24 2016-08-31 Катхолике Университейт Лёвен, К.У. Лёвен Р Энд Д Литический полипептид с пептидогликангидролазной активностью и его применение против инфекций, вызванных грамотрицательными бактериями
DK2563916T3 (en) * 2010-04-27 2015-10-05 Lysando Ag METHOD FOR REDUCING biofilms
EP2468856A1 (en) * 2010-12-23 2012-06-27 Lysando Aktiengesellschaft Antimicrobial Agents
CA2833176C (en) 2011-04-12 2023-05-16 C.B. Appaiah Chimeric antibacterial polypeptides
US9068204B2 (en) 2013-03-15 2015-06-30 The United States Of America, As Represented By The Secretary Of Agriculture Peptidoglycan hydrolase antimicrobials for eradicating lactobacilli that contaminate and reduce ethanol yields in biofuel fermentation
WO2015070912A1 (en) * 2013-11-14 2015-05-21 Lysando Ag Modified el188 endolysin sequence
WO2015070911A1 (en) * 2013-11-14 2015-05-21 Lysando Ag Modified kz144 endolysin sequence
EP3105322B1 (en) 2014-02-14 2018-12-12 Lysando AG Antimicrobial agents
AU2015243359B2 (en) * 2014-04-08 2020-03-12 Lysando Ag Pharmaceutical composition against chronic bacterial infections
GB2543453A (en) 2014-06-26 2017-04-19 Univ Rockefeller Acinetobacter lysins
CN105734029B (zh) * 2014-12-12 2020-09-25 丰益(上海)生物技术研发中心有限公司 磷脂酶抗菌肽
CN108135971A (zh) 2015-09-17 2018-06-08 抗非特公司 溶素恢复/增强在肺表面活性物质存在下由此抑制的抗生素的抗菌活性的用途
CN105175509A (zh) * 2015-10-19 2015-12-23 河南科技学院 一种抗菌肽xyz-1及其应用
CA3014442A1 (en) 2016-02-29 2017-09-08 Dana-Farber Cancer Institute, Inc. Stapled intracellular-targeting antimicrobial peptides to treat infection
CA3022334A1 (en) * 2016-04-28 2017-11-02 Lysando Ag Antimicrobial agents against salmonella bacteria
WO2018100408A1 (en) 2016-11-30 2018-06-07 Sasinapas Co.,Ltd. Modified peptides
JP7033596B2 (ja) * 2016-12-16 2022-03-10 ウニベルシダージ ド ミーニョ 新規エンドリシン
US20180208938A1 (en) * 2017-01-23 2018-07-26 Innate Immunity LLC Compositions and Methods for Protecting Plants Against Bacterial Infections
US11208643B2 (en) * 2017-04-03 2021-12-28 Sasinapas Co., Ltd. Engineered gram-negative endolysins
WO2019018499A2 (en) 2017-07-19 2019-01-24 Dana-Farber Cancer Institute, Inc. ANTIMICROBIAL PEPTIDES STABILIZED FOR THE TREATMENT OF ANTIBIOTIC-RESISTANT BACTERIAL INFECTIONS
WO2019155002A1 (en) * 2018-02-08 2019-08-15 Institut Pasteur Anti-prevotella bacteriocin methods and compositions
CN112368376A (zh) * 2018-03-29 2021-02-12 康特拉费克特公司 溶素-抗微生物肽(amp)多肽构建体、溶素、其分离的编码多核苷酸及其用途
CN108410840A (zh) * 2018-04-03 2018-08-17 大连理工大学 一种铜绿假单胞菌噬菌体内溶素及其编码基因与应用
JP6979210B2 (ja) * 2018-04-26 2021-12-08 株式会社ニューギン 遊技機
JP7515409B2 (ja) * 2018-05-30 2024-07-12 ライサンド アーゲー 新規抗微生物融合タンパク質
AU2019276253A1 (en) 2018-05-30 2020-11-26 Lysando Ag Novel antimicrobial proteins
EP3840771A4 (en) * 2018-08-23 2023-04-19 Contrafect Corporation Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
EP3993821A4 (en) * 2019-07-05 2023-07-19 Contrafect Corporation ANTIMICROBIAL POLYPEPTIDES, BACTERIOPHAGE DERIVATIVES AND THEIR USE AGAINST GRAM-NEGATIVE AND ACID-RESISTANT BACTERIA
CN115605587A (zh) 2020-03-11 2023-01-13 特卢姆治疗有限公司(Es) 新型重组溶素及其在治疗革兰氏阴性菌感染中的用途
CN115942932A (zh) 2020-03-19 2023-04-07 迈克瑞欧斯人体健康有限公司 感兴趣的稳定蛋白
KR102286544B1 (ko) * 2021-02-10 2021-08-05 주식회사 라이센텍 융합 폴리펩타이드 및 이를 포함하는 그람음성균에 대한 항생제
WO2021235876A1 (ko) * 2020-05-22 2021-11-25 주식회사 라이센텍 신규한 폴리펩타이드, 융합 폴리펩타이드, 및 이를 포함하는 그람음성균에 대한 항생제
US20240391964A1 (en) * 2020-07-17 2024-11-28 The University Of Western Australia Compositions and methods for the treatment of cancer
CN111876400B (zh) * 2020-08-06 2022-05-24 昆明理工大学 一种常温裂解酶Sly和编码此酶的多核苷酸
SK289101B6 (sk) * 2020-12-17 2023-08-09 Ústav molekulárnej biológie Slovenskej akadémie vied, verejná výskumná inštitúcia Antimikrobiálny proteín, antimikrobiálny rekombinantný proteín s lytickými vlastnosťami, expresný vektor, spôsob ich prípravy a použitie
US11548917B1 (en) * 2021-11-24 2023-01-10 Intron Biotechnology, Inc. Antibacterial composition effective in treating gram negative bacterial infections and method for preparing the same
WO2024241070A1 (en) 2023-05-22 2024-11-28 L'oreal Cosmetic composition comprising an endolysin and a polyvinyl alcohol
FR3149203A1 (fr) 2023-06-02 2024-12-06 L'oreal Composition anhydre comprenant une endolysine et de l’hydroxypropylmethylcellulose et/ou du pullulane
FR3149202A1 (fr) 2023-06-02 2024-12-06 L'oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et une huile.
FR3149205A1 (fr) 2023-06-02 2024-12-06 L'oreal Composition cosmétique comprenant une endolysine et un agent de charge organique
FR3149209A1 (fr) 2023-06-02 2024-12-06 L'oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un alcool aromatique
WO2024246325A1 (en) 2023-06-02 2024-12-05 L'oreal Cosmetic composition comprising an endolysin derived from a staphylococcus aureus phage and an aromatic alcohol
FR3149208A1 (fr) 2023-06-02 2024-12-06 L'oreal Composition cosmétique, notamment aqueuse, comprenant une endolysine et un pullulane
FR3149206A1 (fr) 2023-06-02 2024-12-06 L'oreal Composition cosmétique aqueuse comprenant une endolysine et du tréhalose
FR3152395A1 (fr) 2023-08-28 2025-03-07 L'oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et la 4-hydroxyacetophenone
FR3149207A1 (fr) 2023-06-02 2024-12-06 L'oreal Composition cosmétique comprenant une endolysine et un composé de formule (I)
FR3149204A1 (fr) 2023-06-02 2024-12-06 L'oreal Composition cosmétique comprenant une endolysine et un tensioactif non ionique comprenant un résidu carbohydrate
FR3152396A1 (fr) 2023-08-28 2025-03-07 L'oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un polyhydroxyalcane
FR3152394A1 (fr) 2023-08-28 2025-03-07 L'oreal Composition cosmétique comprenant une endolysine et des particules d’aérogel de silice hydrophobe
FR3152393A1 (fr) 2023-08-28 2025-03-07 L'oreal Composition cosmétique comprenant une endolysine dérivée d’un phage de Staphylococcus aureus et une charge minérale
WO2025093666A1 (en) 2023-11-01 2025-05-08 University Of Copenhagen Treatment of lymphoma
CN117534733B (zh) * 2024-01-10 2024-03-29 黑龙江八一农垦大学 抗菌肽cm24、重组基因、乳酸工程菌及其应用
CN118895244B (zh) * 2024-07-23 2025-06-20 浙江自贸区中航生物科技有限责任公司 一种提高nk细胞杀伤活性的多肽及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000855A1 (en) * 1999-06-23 2001-01-04 Ppl Therapeutics (Scotland) Ltd. Fusion proteins incorporating lysozyme
WO2005024002A1 (en) * 2003-09-11 2005-03-17 Novozymes A/S Recombinant production of antimicrobial agents
WO2005108563A2 (en) * 2004-04-19 2005-11-17 University Of Chicago Peptidoglycan-hydrolyzing protein encoded by bacteriophage n4
US20060147442A1 (en) * 2003-05-15 2006-07-06 Iogenetics Biocides

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3854476T2 (de) * 1987-07-06 1996-04-04 Univ Louisiana State Inhibierung von eukaryotischen pathogenen und neoplasmen mit lytischen peptiden.
GB8816693D0 (en) 1988-07-13 1988-08-17 Agricultural & Food Res Viral enzyme & gene
GB2255561B (en) 1991-04-20 1995-06-21 Agricultural & Food Res Lysins from bacteriophages
EP0656952B1 (en) * 1992-08-21 2003-03-05 The University Of British Columbia Cationic peptides and method for production
PT778733E (pt) * 1994-09-01 2001-06-29 Novozymes As Composicao proteica basica para matar ou inibir celulas microbianas
US6503881B2 (en) 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6428784B1 (en) 1997-10-31 2002-08-06 New Horizons Diagnostics Corp Vaginal suppository for treating group B Streptococcus infection
US5997862A (en) 1997-10-31 1999-12-07 New Horizons Diagnostics Corporation Therapeutic treatment of group A streptococcal infections
US20030113298A1 (en) * 1997-10-31 2003-06-19 Vincent Fischetti Use of bacterial phage associated lysing proteins for the prophylactic and therapeutic treatment of various illnesses
US6288212B1 (en) * 1998-08-28 2001-09-11 The University Of British Columbia Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor
US5993809A (en) 1998-11-18 1999-11-30 Children's Hospital Medical Center Lysozyme fusion proteins in infections
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
KR20050016362A (ko) 2002-04-22 2005-02-21 다우 글로벌 테크놀로지스 인크. 펩티드의 저비용 생산
US20070207209A1 (en) * 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
US7572602B1 (en) 2004-12-03 2009-08-11 The United States Of America As Represented By The Secretary Of Agriculture Nucleic acid encoding endolysin fusion protein
DE102005040347A1 (de) 2005-08-25 2007-03-01 Profos Ag Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von Listerien
EP2004215B1 (en) 2006-03-31 2010-06-09 The University Court of the University of St. Andrews Anti-microbial compositions comprising a cationic peptide and a glycylglycine endopeptidase
DE102006061002A1 (de) 2006-12-22 2008-06-26 Profos Ag Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von gram-positiven Bakterien
EP3327030B1 (en) * 2007-09-25 2021-07-21 Pastoral Greenhouse Gas Research LTD Vaccines and vaccine components for inhibition of microbial cells
US20100310522A1 (en) 2007-11-26 2010-12-09 Plant Bioscience Limited Novel Polypeptides Having Endolysin Activity and Uses Thereof
EP2318531A4 (en) 2008-07-24 2011-11-09 Us Agriculture TO RESISTANCE DEVELOPMENT REFRACTORY ANTIMICROBIAL ACTIVE SUBSTANCES
EP2157100A1 (en) 2008-08-19 2010-02-24 Profos AG Artificial peptidoglycan lysing enzymes and peptidoglycan binding proteins
GB0815484D0 (en) 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
EP2393481B1 (en) * 2009-02-03 2019-04-17 Applied Biomimetic A/S Nanofabricated membrane using polymerized proteoliposomes
WO2010091294A2 (en) 2009-02-05 2010-08-12 The Regents Of The University Of California New targeted antimicrobial moieties
US8383102B2 (en) 2009-05-21 2013-02-26 The United States Of America As Represented By The Secretary Of Agriculture Fusion of peptidoglycan hydrolase enzymes to a protein transduction domain allows eradication of both extracellular and intracellular gram positive pathogens
WO2010149795A1 (en) 2009-06-26 2010-12-29 Lysando Holding Establishment Antimicrobial agents
EP3714895A3 (en) 2009-06-26 2020-11-25 Lysando AG Antimicrobial agents
EA024253B1 (ru) 2009-08-24 2016-08-31 Катхолике Университейт Лёвен, К.У. Лёвен Р Энд Д Литический полипептид с пептидогликангидролазной активностью и его применение против инфекций, вызванных грамотрицательными бактериями
DK2563916T3 (en) 2010-04-27 2015-10-05 Lysando Ag METHOD FOR REDUCING biofilms
WO2014001571A1 (en) 2012-06-29 2014-01-03 Lysando Ag Composition for use in mycobacteria diagnosis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000855A1 (en) * 1999-06-23 2001-01-04 Ppl Therapeutics (Scotland) Ltd. Fusion proteins incorporating lysozyme
US20060147442A1 (en) * 2003-05-15 2006-07-06 Iogenetics Biocides
WO2005024002A1 (en) * 2003-09-11 2005-03-17 Novozymes A/S Recombinant production of antimicrobial agents
WO2005108563A2 (en) * 2004-04-19 2005-11-17 University Of Chicago Peptidoglycan-hydrolyzing protein encoded by bacteriophage n4

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARIMA H., IBRAHIM H.R., KINOSHITA T. KATO A.: "Bactericidal action of lysozymes attached with various sizes of hydrophobic peptides to the C-terminal using genetic modification", FEBS LETTERS, ELSEVIER, AMSTERDAM., NL, vol. 415, no. 1, 22 September 1997 (1997-09-22), NL, pages 114 - 118, XP004261147, ISSN: 0014-5793, DOI: 10.1016/S0014-5793(97)01071-5 *
DONOVAN D M, ET AL: "Peptidoglycan hydrolase fusions maintain their parental specificities", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 72, no. 4, 1 April 2006 (2006-04-01), US, pages 2988 - 2996, XP002582772, ISSN: 0099-2240, DOI: 10.1128/AEM.72.4.2988-2996.2006 *
IBRAHIM H R, ET AL: "Enhanced bactericidal action of lysozyme to Escherichia coli by inserting a hydrophobic pentapeptide into its C terminus.", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 269, no. 7, 18 February 1994 (1994-02-18), pages 5059 - 5063, XP002579297, ISSN: 0021-9258 *
VAN DER LINDEN DANITSJA S ET AL: "Synergistic effects of ovine-derived cathelicidins and other antimicrobials against Escherichia coli O157:H7 and Staphylococcus aureus 1056 MRSA.", BIOTECHNOLOGY LETTERS, SPRINGER NETHERLANDS, DORDRECHT, vol. 31, no. 8, 1 August 2009 (2009-08-01), Dordrecht, pages 1265 - 1267, XP002604248, ISSN: 1573-6776, DOI: 10.1007/S10529-009-0010-9 *

Also Published As

Publication number Publication date
CA2764131A1 (en) 2010-12-29
CN105440139A (zh) 2016-03-30
AU2018201931A1 (en) 2018-05-31
WO2010149792A3 (en) 2011-02-24
US20120189606A1 (en) 2012-07-26
JP2012530509A (ja) 2012-12-06
SI2445515T1 (sl) 2016-08-31
US8906365B2 (en) 2014-12-09
EP3058950A2 (en) 2016-08-24
IL250938A0 (en) 2017-04-30
EA201270079A1 (ru) 2012-06-29
CN102458452B (zh) 2015-12-02
DK2445515T3 (en) 2016-07-04
KR20120095345A (ko) 2012-08-28
KR101711062B1 (ko) 2017-02-28
US11052137B2 (en) 2021-07-06
PL2445515T3 (pl) 2016-10-31
CA2764131C (en) 2022-05-10
CN102458452A (zh) 2012-05-16
US20190209663A1 (en) 2019-07-11
BRPI1015192A2 (pt) 2019-09-17
EP3058950A3 (en) 2016-10-12
KR20170024129A (ko) 2017-03-06
AU2016202296A1 (en) 2016-05-12
AU2016202296B2 (en) 2017-12-21
EP3714895A2 (en) 2020-09-30
MX2011013288A (es) 2012-02-28
JP6034187B2 (ja) 2016-11-30
EP3058950B1 (en) 2020-03-04
EP3714895A3 (en) 2020-11-25
HK1169311A1 (zh) 2013-01-25
IL250938B (en) 2019-12-31
SG177370A1 (en) 2012-02-28
EP2445515B1 (en) 2016-04-06
AU2010264656B2 (en) 2016-01-21
MX360300B (es) 2018-10-29
IL217124A0 (en) 2012-02-29
AU2010264656A1 (en) 2011-12-08
JP2017008033A (ja) 2017-01-12
IL217124A (en) 2017-03-30
ES2579806T3 (es) 2016-08-16
US20150118731A1 (en) 2015-04-30
EP2445515A2 (en) 2012-05-02
CN105440139B (zh) 2019-08-13
US10137175B2 (en) 2018-11-27
WO2010149792A2 (en) 2010-12-29
AU2018201931B2 (en) 2019-08-15

Similar Documents

Publication Publication Date Title
AU2018201931B2 (en) Antimicrobial Agents
EP2446028B1 (en) Antimicrobial agents
CN102575240B (zh) 新的细胞内溶素OBPgpLYS
CA2822732C (en) Antimicrobial fusion proteins
HK1169311B (en) Antimicrobial agents
HK1224571A1 (en) Antimicrobial agents
HK1224571A (en) Antimicrobial agents
HK1224571B (en) Antimicrobial agents
HK1190430A (en) Antimicrobial agents
HK1190430B (en) Antimicrobial agents

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM